Home > Journals > Minerva Surgery > Past Issues > Minerva Chirurgica 2013 April;68(2) > Minerva Chirurgica 2013 April;68(2):169-74



Publishing options
To subscribe
Submit an article
Recommend to your librarian





Minerva Chirurgica 2013 April;68(2):169-74


language: English

Impact of adjuvant chemotherapy in completely resected stage IIIA non-small cell lung cancer

Naim Younes R. 1, Gross J. L. 2, Abrao F. C. 3, Rodrigues Pereira J. 2

1 Department of Surgery, Oncology Center of Hospital Sao Jose, University of Sao Paulo, Sao Paulo, Brazil; 2 Department of Thoracic Surgery of Hospital A.C. Camargo, São Paulo, Brazil; 3 Department of Thoracic Surgery, Oncology Center of Hospital Sao Jose, Hospital Santa Marcelina, São Paulo, Brazil


Aim: Outcome of patients with locally advanced non-small-cell lung cancer (NCSLC) is generally poor, with five-year survival rate of only 23%, when patients are treated with surgery only. The presentation of positive adjuvant therapy trials in NSCLC has changed clinical practice, doubling the number of patients with completely resected NSCLC referred for adjuvant chemotherapy since 2004. Furthermore, few large studies described a large number of stage III patients in non-Asiatic patients and they showed controversial results about survival in completely resected stage IIIA NSCLC. The objective of this study was to evaluate the impact of adjuvant chemotherapy in completely resected stage IIIA NCSLC, administered on a routine basis, outside clinical trials.
Methods: This is a retrospective study of patients with stage IIIA NCSLC treated between 1990 and 2008, and included in a continuous, consecutive database. Inclusion criteria were: age >18 years, complete surgical resection, and pathologically confirmed as stage IIIA. The following clinical data were obtained: age, gender, performance status, histological type, chemotherapy regimens, status at last follow-up and hospital where the treatment occurred. Kaplan-Meier’s method was used to determine actuarial survival. Differences in survival were determined by Breslow and log rank analyses.
Results: According to these inclusion criteria, 415 patients were considered for the present study. The median follow-up time of all patients was 38.2 months. The adjuvant chemotherapeutic treatment affected survival significantly (P <0.001). Also the type of chemotherapeutic treatment affected survival (P ≤0.001).
Conclusion: Cisplatin-based adjuvant chemotherapy was beneficial in patients who had a completed resected stage IIIA carcinoma.

top of page